# Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD

Study · id `cardio:ct-nct04591392` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04591392](<https://clinicaltrials.gov/study/NCT04591392>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04591392

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 250 participants.

## Technical summary

Registry record NCT04591392. Allocation not applicable; no masking; primary purpose treatment. Start 2021-03-12 (actual); primary completion 2027-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 250 participants (planned count; ClinicalTrials.gov record NCT04591392, source copy `cardio:ctgov-nct04591392-2025-05-07`, retrieved 2026-10-26)
- Started: 2021-03-12 (actual) (ClinicalTrials.gov record NCT04591392, source copy `cardio:ctgov-nct04591392-2025-05-07`, retrieved 2026-10-26)
- Primary completion: 2027-03 (anticipated) (ClinicalTrials.gov record NCT04591392, source copy `cardio:ctgov-nct04591392-2025-05-07`, retrieved 2026-10-26)
- Completion: 2032-03 (anticipated) (ClinicalTrials.gov record NCT04591392, source copy `cardio:ctgov-nct04591392-2025-05-07`, retrieved 2026-10-26)
- Countries: United States; Canada; France; Switzerland (ClinicalTrials.gov record NCT04591392, source copy `cardio:ctgov-nct04591392-2025-05-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04591392-2025-05-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD
- Acronym: ASCENT ASD
- Condition: Heart Septal Defect
- Condition: Heart Septal Defects, Atrial
- Condition: Heart Defects, Congenital
- Condition: Cardiovascular Abnormalities
- Condition: Cardiovascular Diseases
- Condition: Heart Diseases
- Condition: Congenital Abnormalities
- Intervention (Device): reSept ASD Occluder
- Lead sponsor: atHeart Medical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)

## Provenance

Content hash: f2b5b76708875060cda3bf32c02b7c317f328dfe32bc0bbde4efc14a717bd011
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
